The HDM2 oncoprotein is a cellular inhibitor of p53 and is frequently deregulated in human cancer. However, the HDM2 gene encodes alternatively spliced variants whose functional significance is poorly understood. We had previously reported the detection of alternative HDM2 forms in Hodgkin's lymphoma (HL)-derived cell lines. Here, we have cloned several of these transcripts, including the previously described HDM2-A, -B and -C (which encode the COOH terminus of HDM2), and two novel variants (HDM2-HL1 and -HL2) containing a complete p53 interaction domain. Real-time PCR assays demonstrated that HDM2-A and -B were selectively expressed by HL cell lines and primary tumors, compared with their non-neoplastic counterparts. In transient transfection experiments, alternatively spliced HDM2 isoforms were partially or totally localized within the cytoplasm. HDM2-HL2 was able to inhibit transactivation of a p53-inducible reporter construct and induced a partial relocalization of p53 to the cytoplasm. Expression of HDM2-A and -B caused the activation of p53/p21 and induced growth arrest in primary cells, but also increased the expression levels of cyclins D1 and E. Other possible genes regulated by HDM2-A and -B were identified using cDNA microarray technology. These results imply that HDM2 isoforms may have multiple effects on cell cycle control, and provide insight into the mechanisms through which these molecules contribute to tumorigenesis.
Introduction
The best-characterized function of the HDM2 oncoprotein (the human homolog of mouse MDM2) is the negative regulation of p53, which is achieved through multiple mechanisms. The interaction of these two proteins through their NH 2 termini results in the inhibition of p53-induced transactivation (Momand et al., 1992) . Additionally, the COOH-terminal RINGfinger domain of HDM2 has E3 ubiquitin ligase activity that targets p53 for proteasomal degradation (Haupt et al., 1997; Kubbutat et al., 1997) . In response to genotoxic or oncogenic stress, the interaction between p53 and HDM2 is disrupted by phosphorylation or antagonized by p14 ARF , respectively, resulting in the activation of a p53-mediated response (Momand et al., 2000) . HDM2 is itself a transcriptional target of p53, which creates a negative feedback loop that regulates p53 activity and stability (Wu et al., 1993) . While p53 is mutated in B50% of human cancers (Soussi and Beroud, 2001 ), overexpression of HDM2 may be an alternative mechanism of p53 inactivation. In fact, amplification of the HDM2 gene is relatively frequent in human tumors, especially -but not exclusively -in sarcomas (Oliner et al., 1992; Momand et al., 1998) . Furthermore, HDM2 is overexpressed independently of gene amplification in diverse tumors, such as B-cell lymphomas and leukemias (Watanabe et al., 1994) .
Nevertheless, various lines of evidence suggest that HDM2 may have additional functions, unrelated to p53 regulation. HDM2 has been reported as interacting with several proteins, including Rb, E2F1/DP1, CBP/p300, p14 ARF , p73, Numb, MTBP, L5, as well as with nucleic acids (Momand et al., 2000) . Thus, HDM2 can stimulate the activity of E2F (Martin et al., 1995) and regulate that of p73 (Ongkeko et al., 1999) . Overexpression of MDM2 in transgenic mice increases the incidence of sarcomas regardless of p53 status, suggesting a p53-independent mechanism of MDM2-induced tumorigenesis (Jones et al., 1998) .
The complexity of this system is further revealed by the observation that HDM2 is alternatively spliced in a variety of human cancers, including ovarian and bladder carcinomas (Sigalas et al., 1996) , glioblastomas (Matsumoto et al., 1998; Kraus et al., 1999) , breast cancer (Hori et al., 2000; Lukas et al., 2001) , sarcomas (Bartel et al., 2000 (Bartel et al., , 2001 Tamborini et al., 2001) , nonsmall cell lung carcinomas (Evans et al., 2001) and giant cell tumors of bone (Evdokiou et al., 2001) . Many HDM2 splicing variants have been sequenced (for a review see Bartel et al., 2002) , most of which encode proteins lacking internal sequences including a variable fragment of the p53 binding domain, and some of these proteins have been shown to be unable to interact with p53. The expression of alternative HDM2 forms has been associated with tumorigenesis (these forms were rarely detected in normal cells) and tumor progression (they were detected at a higher frequency in tumors of high stage and grade) (Sigalas et al., 1996; Matsumoto et al., 1998) . The expression of aberrantly spliced (i.e. spliced at cryptic intraexonic or intronic sites) HDM2 transcripts was associated with adverse clinical outcome in breast carcinomas, whereas the expression of an alternatively spliced form (HDM2-B) was not related to outcome and was also detected in normal breast epithelium (Lukas et al., 2001) .
Several reports have attempted to elucidate the biological functions of HDM2 splicing variants but have yielded conflicting results. Several HDM2 transcripts were initially reported as having oncogenic properties in NIH/3T3 cells (Sigalas et al., 1996) . A different report demonstrated that MDM2-B could stimulate the proliferation of mouse embryo fibroblasts (MEF) of different genotypes and had antiapoptotic activity (Steinman et al., 2004) . However, other authors failed to detect any oncogenic activity of HDM2 isoforms in vitro (Fridman et al., 2003) ; moreover, some transcripts cloned from murine Em-myc lymphomas were shown to inhibit cell growth (Dang et al., 2002) . Conversely, expression of several MDM2 isoforms induced tumorigenesis in two different mouse models (Fridman et al., 2003; Steinman et al., 2004) . Even though these observations seem to suggest that HDM2 isoforms can play a role in carcinogenesis, at least in some cellular/tissular contexts, the molecular mechanism by which they exert their oncogenic effects is poorly understood. There has been a similar controversy concerning the function of full-length HDM2 (HDM2-FL), which appears to have antiproliferative properties under some conditions (Brown et al., 1998) .
We previously reported the expression of some HDM2 splicing variants by several cell lines derived from Hodgkin's Lymphoma (HL), a lymphoid neoplasia in which HDM2 is frequently overexpressed, while the incidence of p53 mutations is remarkably low . We have now extended this observation by analysing the expression of alternatively spliced HDM2 forms in lymphoma cell lines and in normal and neoplastic human lymphoid tissues, and we have performed a series of experiments in order to elucidate the properties and functions of several of these HDM2 isoforms.
Results
Expression of alternatively spliced HDM2 transcripts in lymphoid cells and tissues In a previous report , we noted the presence of alternatively spliced HDM2 transcripts (HDM2-A, -B, -C and -D) in four HL-derived cell lines. Therefore, we have analysed a larger group of lymphoid cell lines including five HL-derived (the four lines analysed in the initial report, plus an additional one), one lymphoblastoid, and eight NHL-derived cell lines. RNA extracted from these cells was subjected to RT-PCR using nested primers designed to amplify the complete coding region of HDM2. In addition to the complete transcript (HDM2-FL), several shorter products were detected in most lymphoma cell lines regardless of their origin (HL or NHL, B-or T-cell), the mutational status of p53, or the presence of alterations at the p14 ARF locus (Figure 1a) .
The HDM2 gene can be transcribed from two different promoters, P1 (p53-independent) and P2 (p53-responsive), leading to the use of two alternative first exons (exons 1 and 2), both of which are noncoding (Barak et al., 1994) . Since splicing regulation may be influenced by promoter structure (Smith and Valcarcel, 2000) , and given that the primers used in the RT-PCR assays specifically amplify P1-derived transcripts, a new set of nested primers was designed in order to amplify only P2-derived transcripts. The analysis of several cell lines with these P2-specific primers revealed a similar pattern of splicing (Figure 1b) , suggesting that P1-and P2-transcripts are spliced in a similar way.
Additionally, we performed a nested RT-PCR analysis of RNAs extracted from a group of tissue samples of HL and reactive lymphoid tissue, using primers specific for P1 (Figure 1c ). Of 24 HL samples in which we detected full-length HDM2 (1526 base pairs [bp]), 14 (58%) had at least one additional RT-PCR band. In the vast majority of these samples we detected one or more bands larger than 1100 bp, which is not consistent with the transcripts originally described by Sigalas et al. (1996) . In addition, five of these samples expressed different combinations of shorter products, the sizes of which were consistent with those of HDM2-A to -D. We also detected alternative HDM2 products in normal tissue samples at a similar frequency (9 out of 15 samples, 60%). These bands predominantly represented transcripts larger than 1100 bp, although two samples seemed to express HDM2-C and -D.
Cloning and sequencing of several RT-PCR products led to the identification of a group of transcripts (Figure 1d ), which can be considered to be alternatively spliced products of the HDM2 gene. These transcripts (with the exception of MDM2-D, which was aberrantly spliced) had donor-acceptor sites corresponding to natural intron-exon borders, and the acceptor site was located at the 5 0 end of exons 10 or 12. Two of the identified transcripts (HDM2-HL1 and -HL2) have not been previously described, whereas the other four molecules have been reported by different authors.
The structure of the proteins that would result from the translation of each transcript is shown in Figure 1d . HDM2-A, -B, -C and -D do not encode the entire NH 2 -terminal domain, which is involved in the interaction with p53, p73 and E2F1/DP1, but they preserve an intact COOH-terminal RING domain. On the other hand, HDM2-HL1 and -HL2 encode a complete p53 binding domain but, in the case of -HL2, a frameshift results in the appearance of a premature stop codon that truncates the central and COOH-terminal regions of the protein. The figure also shows the position of the inhibitory domains (ID1 and ID2) defined by Brown et al. (1998) . While ID1 is only encoded by HDM2-HL1, ID2 is preserved in HDM2-A and -C. In fact, ID2 roughly overlaps with the fragment lost in HDM2-HL1.
With the purpose of obtaining a more precise comparison of the HDM2 splicing pattern between tumoral and nontumoral cells, we designed primer pairs that allowed the specific amplification of several individual transcripts (HDM2-FL, -A, -B and -HL2), using a quantitative RT-PCR technique to determine their relative levels of expression ( Figure 2 ). The samples analysed included the five HL-derived cell lines, a lymphoblastoid cell line, nontumoral lymphoid tissue (eight samples) and HL-affected tissues (11 samples). HDM2-FL mRNA was detected in all samples and, although its levels were variable, they were not significantly different between benign and neoplastic samples. The expression levels of HDM2-A and -B varied widely among the five HL cell lines, although they were much higher on average than those detected in LCL-HO. Moreover, these two transcripts were expressed by a group of HL samples, but were virtually undetectable in normal tissues. This supports previous findings in other tumor types suggesting that these splicing forms are tumor-specific. In contrast, the pattern of expression of HDM2-HL2 was parallel to that of HDM2-FL, and normal tissues expressed a similar amount of this transcript to that expressed by the HL cell lines and primary samples. This implies that some, but not all, splicing events of the HDM2 gene occur specifically in transformed lymphoid cells.
Characterization of the proteins encoded by alternative HDM2 transcripts Four HDM2 transcripts (HDM2-FL, -HL2, -A and -B) were cloned into a mammalian expression vector and transfected into H1299 cells. First, we evaluated the reactivity of the expressed proteins with two antibodies generated against HDM2-FL, SMP14 and Ab-6, which recognize epitopes mapped to amino acids 154-167 and 383-491 of human HDM2, respectively ( Figure 1d ). SMP14 detected, in addition to HDM2-FL, a 30-kDa protein encoded by HDM2-HL2. Proteins encoded by HDM2-A (B60 kDa) and HDM2-B (B45 kDa) did not HDM2 splicing variants in Hodgkin's lymphoma A Sánchez-Aguilera et al react with SMP14 but were detected by Ab-6, and were seen as doublets, the lower band probably representing a degradation product (Figure 3a ). This confirms that these transcripts, when expressed exogenously, are translated into proteins with the expected primary structure.
It was important to demonstrate whether HDM2 isoforms were expressed endogenously at the protein level. Therefore, protein extracts from several untransfected cell lines were immunoblotted with these two antibodies. Multiple proteins were detected, some of which exhibited approximately the same pattern of electrophoretic migration as the transfected isoforms. Particularly, one B60-kDa band, similar in size to HDM2-A and detected by Ab-6, was expressed by all of the transformed cell lines tested (including HL-derived, NHL-derived, and SV40-transformed VA-13 fibroblasts), but was not detected in primary human fibroblasts (BJ), EBV-immortalized B-cells (Figure 3b ) or the lymphoblastoid cell line LCL-HO (not shown). This pattern of expression is consistent with that observed for HDM2-A in the quantitative PCR assay (Figure 2 ).
The subcellular localization of HDM2-FL and the three splicing variants was determined in transiently transfected H1299 (Figure 4a ) and NIH/3T3 cells (data not shown). Whereas the localization of HDM2-FL was predominantly nucleoplasmic, HDM2-A and -B were mainly localized within the cytoplasm. This finding is consistent with the lack of the central NLS in these splicing variants. In spite of the fact that HDM2-HL2 also lacks the NLS, this isoform was detected in both the nucleus and the cytoplasm. A previous report (Evans et al., 2001) suggested that HDM2-B could interact with HDM2-FL and sequester it into the cytoplasm. We confirmed that overexpressed HDM2-B was able to relocate endogenous nuclear HDM2-FL to the cytoplasm in H1299 and U2OS cells, and HDM2-A also displayed this activity (Figure 4b) .
The HDM2-HL2 transcript encodes only the first 170 aminoacids from HDM2-FL, including the p53 interaction domain. In order to determine whether this isoform could regulate p53 activity, the p53-null cell line H1299 was cotransfected with p53, HDM2-HL2 (or -FL and -A as controls), and a luciferase reporter vector derived from the p21 promoter. The specific activation of this 
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A Sánchez-Aguilera et al reporter by p53 was dose-dependently inhibited by overexpressed HDM2-FL and also, to a similar extent, by HDM2-HL2 (but not by HDM2-A, which lacks the p53 interaction domain) (Figure 3c) . Moreover, overexpression of HDM2-HL2 induced a partial relocalization of p53 to the cytoplasm (Figure 4c ). These data imply that HDM2-HL2 can function as a negative regulator of p53 activity.
Effects of HDM2 variants on proliferation and cell cycle regulation In order to study the impact of the expression of HDM2 isoforms on cell proliferation, primary human fibroblasts (BJ) were infected with retroviruses encoding HDM2-FL, -A or -B, or with an empty vector as a control, and the growth properties of stably transduced cells were analysed. Expression of HDM2-A and -B reduced the proliferation rate of BJ cells and caused a decrease in the proportion of cells in the S and G 2 /M phases of the cell cycle (Figure 5a ). HDM2-A and -B also inhibited the proliferation of primary, wild-type MEF, but did not arrest p53-deficient MEF, suggesting that the antiproliferative effect could be p53-dependent (Figure 5b ).
In an attempt to determine the molecular changes associated with the expression of HDM2 isoforms, we used cDNA microarray hybridization to determine the gene expression profile of BJ cells transduced with HDM2-A or -B, compared with empty vector infection. The genes whose expression was significantly induced (log 2 ratio>0.8) after HDM2-A/B overexpression in two independent experiments are shown in Table 1 . This group of genes includes both antiproliferative genes (CDKN1A, IGFBP6) and genes related with cell-cycle progression and proliferation (CCND1, TIMP1, and two histone genes). Remarkably, two of the most highly induced genes were CCND1 (cyclin D1) and CDKN1A (p21), two important regulators of the G1/S transition. Genes that were downregulated after HDM2-A/B expression showed only moderate differences in expression and included several genes involved in DNA synthesis and mitosis (TOP2A, BUB1, BUB1B, RRM2, CCNA2, STK6, CDC25C, CDK1 and DCK, MAD2L1). These findings prompted us to examine cell-cycle regulation by HDM2-A/B in more detail.
Therefore, we analysed the changes in the expression of several cell-cycle regulatory proteins in response to these HDM2 isoforms (Figure 5c ). Expression of HDM2-A and -B induced a slight accumulation of p53 accompanied by an increase in the levels of p21 -but not p27 -suggesting that these short HDM2 forms may activate a p53 response in primary cells. This effect was hardly detectable in the luciferase assay (Figure 3c ), probably because p53 was ectopically expressed in that experiment. The expression levels of cyclin A2 (Figure 5c ), cyclin B1 and CDK1 (not shown) were reduced, which is consistent with the growth-inhibitory effect. However, expression of HDM2-A and -B caused an increase in the levels of two proteins involved in the promotion of cell cycle progression: cyclin D1 (validating the microarray results) and cyclin E. This, together with the role of p21 as an assembly factor for CDK4/ cyclin D1 complexes, is consistent with a role of HDM2-A/B in cell cycle promotion and oncogenesis.
Discussion
The expression of alternatively spliced HDM2 forms appears to be a widespread phenomenon in lymphoma cell lines of different subtypes, and can be detected not only in cell lines but also in primary HL-affected tissues. Moreover, our results suggest that some HDM2 isoforms can be detected at the protein level. Together with the detection of several HDM2 mRNAs by northern blot (Maxwell, 1994; Pinkas et al., 1999) , this seems to rule out the possibility that alternative HDM2 transcripts are merely RT-PCR artifacts.
More than 40 HDM2 isoforms have been described (Bartel et al., 2002 ). An appreciation of this apparently complex system may be aided by dividing these isoforms into two groups, on the basis of structural and, presumably, functional similarities: (1) Many transcripts encode the complete p53 interaction domain or most of it. These proteins, exemplified by HDM2-HL2 in our study, can function as negative regulators of p53. However, they differ from HDM2-FL in that they often lack the ubiquitin ligase domain (which targets p53 for proteasomal degradation) and can only inhibit p53 transcriptional activity through direct interaction, which may involve a partial relocalization of p53 to the cytoplasm. (2) Transcripts encoding the COOH terminus but not the p53 binding domain (such as the most commonly expressed transcripts HDM2-A and -B) appear to induce a more complex cellular response.
On one hand, their expression appears to elicit an antiproliferative response in normal cells, which may involve the activation of p53/p21. One hypothesis to explain this is that HDM2-A/B interact with HDM2-FL and sequester it into the cytoplasm, leading to the activation of nuclear p53 (Figure 4b ) (Evans et al., 2001) . Additionally, we observed that HDM2-A/B downregulated several transcriptional targets of E2F (cyclin A2, CDK1, MAD2L1) suggesting that the inhibitory effects of HDM2-A/B may occur at the level of E2F regulation (probably through the p21-mediated inhibition of CDK2). On the other hand, HDM2-A and -B seem to induce an increase in the levels of two molecules involved in 
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A Sánchez-Aguilera et al cell-cycle progression, cyclins D1 and E. This may be the molecular basis for the proposed tumorigenic activity of HDM2-A/B; the oncogenic role of these two cyclins and their activation/overexpression in human cancer has been well documented. In addition to their role in the promotion of cell-cycle progression, deregulated cyclins D1 and E promote chromosomal instability, aneuploidy and mitotic spindle abnormalities (Nelsen et al., 2004; Rajagopalan et al., 2004) . Interestingly, p21 (also induced by HDM2-A/B) is an assembly factor for CDK4/cyclin D1 complexes and can function in a positive fashion in cell proliferation and inhibition of apoptosis (Weiss, 2003) . Moreover, cyclins D1 and E are often highly expressed by neoplastic cells in HL (Garcia et al., 2003; Tzankov et al., 2003) . The expression of cyclin D1 is most remarkable, since this cyclin is not expressed in the lymphoid compartment and only rarely in lymphomas (with the exception of t(11;14) positive tumors). This raises the possibility that HDM2-A/B may contribute, at least in part, to the malignant phenotype of Reed-Sternberg cells. Interestingly, other genes that we found to be regulated by HDM2-A/B may also be related to the biology of HL. TIMP1 is expressed by HL cells and functions as an autocrine/paracrine survival factor (Oelmann et al., 2002) . The IL13RA2 receptor binds IL13, which has been described as a critical growth factor for HL cells (Kapp et al., 1999) .
The dual function of the HDM2 isoforms encoding the COOH-terminal domain is reminiscent of the opposite cellular responses triggered by oncogenes like Ras (Serrano et al., 1997) , and could partially explain why different studies of their function have yielded apparently contradictory results. Previous reports have used different cellular models that may respond differently to the expression of HDM2 isoforms. The negative effect of HDM2-A/B on cell growth appears to be dominant when these forms are overexpressed in normal cells, while their oncogenic function may reveal itself in the presence of cancer-related alterations that cancel the antiproliferative response, such as p53 inactivation. Overexpression of HDM2 is partially equivalent to p53 inactivation; therefore, splice variants may also cooperate with HDM2-FL in tumorigenesis, which is consistent with the fact that HDM2-FL and the short forms, HDM2-A/B, are usually expressed simultaneously. A model showing how different HDM2 isoforms can regulate both the p53 and Rb pathways is proposed in Figure 5d .
In conclusion, our results may help us to understand the biological role of the HDM2 splicing variants and the mechanisms through which they contribute to tumorigenesis in general, and in HL in particular. The precise mechanisms of regulation of cyclins D1/E and p53 by HDM2-A/B, and the regulation of the process of HDM2 mRNA splicing, are topics of interest that need to be dealt with in future studies.
Materials and methods

Cell lines, cell culture, and transfections
The HL-derived cell lines (L-540, HDLM-2, L-428, KM-H2 and HD-MY-Z), LCL-HO (lymphoblastoid, EBV-transformed), and most non-Hodgkin's-Lymphoma (NHL)-derived cell lines were purchased from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany). The cell lines H1299 (nonsmall cell lung carcinoma), U2OS (osteosarcoma), NIH/3T3 (mouse fibroblast), BJ and VA-13 (human fibroblast) were obtained from the American Type Culture Collection (Rockville, MD). Phoenix-Ampho cells, primary MEF (mixed background, Cd1/129), and p53À/À MEF were provided by the CNIO's Experimental Oncology and Tumor Suppression laboratories. Cells were cultured in RPMI or DMEM media supplemented with 10-20% fetal bovine serum and antibiotics.
H1299 and U2OS cells were transfected with Lipofectaminet 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Phoenix-Ampho and NIH/3T3 cells were transfected by a standard calcium phosphate precipitation method. Gene transfer to human and mouse fibroblasts was achieved by retroviral infection (see below).
Tissue samples
Frozen tissue samples were provided by the CNIO Tumour Bank Network, and comprised 28 cases of HL and 20 samples of normal lymphoid tissue (reactive tonsils, lymph nodes and thymus). HDM2 splicing variants in Hodgkin's lymphoma A Sánchez-Aguilera et al tion cycles (1 min at 951C, 30 s at 551C, 2 min at 721C), and a final extension step (10 min at 721C). We used previously described PCR primers (Matsumoto et al., 1998) Values were normalized to the expression of TATA box binding protein (TBP) as an endogenous control; the primers and fluorescent probe for the amplification of TBP were purchased from Applied Biosystems as Pre-Developed Taqman Assay Reagents. Standard curves were constructed for all amplicons and each measurement was performed in triplicate. PCR reactions were run and analysed using the ABI Prism 7700 Sequence Detection System (Applied Biosystems). Reaction conditions were as follows: 2 min at 501C, 10 min at 951C, and 55 amplification cycles (15 s at 951C, 1 min at 601C). PCR products were checked by electrophoresis on 3% agarose gels.
Plasmids
Four HDM2 transcripts (HDM2-FL, -HL2, -A, and -B) were excised from pCR2.1 and subcloned into the EcoRI site of the pcDNA3 expression vector (Invitrogen). For retroviral expression, HDM2 transcripts (BamHI-XhoI fragments from pcDNA3) were subcloned between the BamHI and SalI sites of the pBABE-puro vector. The reporter vector p21-cfos-luc has been described previously (Di Como et al., 1999) . The pSV-bgalactosidase control vector was provided by Promega (Madison, WI).
Retrovirus production and infections
Amphotropic Phoenix-Ampho packaging cells (about 80% confluent) were transfected in 10-cm plates with 25 mg of retroviral expression vector. Viral supernatants were produced at 371C, collected 48 h after transfection and then filtered (0.45 mm). Target cells were plated on the day before transfection at 500 000 cells per 10-cm plate, and infected with the undiluted viral supernatants supplemented with 6 mg/ml polybrene (Sigma, St Louis, MO). After a 16-h incubation with the virus at 371C, the supernatant was replaced with fresh medium. Beginning 48 h after the infection, cells were selected with 2 mg/ml puromycin (Sigma) for 2-3 days, then trypsinized and plated for subsequent assays.
Cells were collected on days 5-6 postinfection and processed for RNA and protein extraction and flow cytometry. For growth curves, cells were plated at a density of 50 000 cells/well in six-well plates, in duplicate or triplicate, and counted every 24 h. For cell-cycle analysis, trypsinized cells were fixed in 70% ethanol, treated with RNase A, stained with propidium iodide (Sigma) and analysed with a FACScalibur flow cytometer (BD Biosciences, San Jose, CA).
Western blot, immunofluorescence, and luciferase assays For immunoblotting, cells were lysed in RIPA buffer. Lysates were electrophoresed in 12% SDS-PAGE gels and transferred overnight onto nitrocellulose membranes (Amersham, Buckinghamshire, UK). Membranes were blocked, sequentially incubated with primary and peroxidase-conjugated secondary antibodies and developed with ECL western blotting detection reagents (Amersham).
For immunofluorescence, cells were grown on glass coverslips in 12-well plates. At 24 h after transfection, cells were fixed in 4% paraformaldehyde for 10 min, permeabilized with 0.5% Triton X-100 in PBS, and blocked in calf serum. Cells were then sequentially incubated at room temperature with the primary antibodies for 1 h and a 1:100 dilution of the secondary antibodies (Alexa Fluor 594 goat anti-mouse IgG 1 and/or Alexa Fluor 488 goat anti-mouse IgG 2a (Molecular Probes, Eugene, OR)) for 1 h. Finally, preparations were counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI) (Molecular Probes) and visualized under a TCS-SP2-AOBS-UV confocal microscope (Leica Microsystems, Bannockburn, IL).
For luciferase assays, H1299 cells were transfected in 24-well plates, in triplicate, with p21-cfos-luc (200 ng), pSV-b-galactosidase (100 ng), and expression vectors for p53 (5 ng) and HDM2 isoforms. The total amount of DNA was adjusted to 800 ng with empty pcDNA3 vector. Cells were lysed 24 h after transfection, and luciferase and b-galactosidase activities were determined using reagents from Promega (Luciferase Assay and b-Galactosidase Assay systems, respectively).
cDNA microarrays Double-stranded cDNA was synthesized from total RNA and transcribed in vitro using the MEGAscriptt T7 kit (Ambion, Austin, TX) to yield amplified antisense RNA (aRNA). aRNA (2.5 mg) were used as a template to synthesize fluorescently labeled cDNA (Cy3 or Cy5), which was hybridized onto CNIO OncoChip cDNA microarrays. A detailed description of the OncoChip and the labeling/hybridization protocol is provided elsewhere (Tracey et al., 2002) . The Cy5/Cy3 intensity ratios were quantified using the GenePix Pro 4.0 program (Axon Instruments, Union City, CA) and normalized to the mean ratio value of all spots in the array. The base-2 logarithm of the ratios were calculated, replicated spots were averaged and inconsistent replicates were removed. All data analyses were performed using public software created by the CNIO Bioinformatics Unit (http://gepas.bioinfo.cnio.es).
Antibodies
The following antibodies were used in this study: HDM2 (SMP14, sc-965), p53 (DO-1, sc-126), p27 (C-19, sc-528) , and cyclin E (C-19, sc-198) , from Santa Cruz Biotechnology (Santa Cruz, CA); HDM2 (Ab-6, clone 5B10C) and p21 (Ab-1, clone EA10), from Calbiochem (San Diego, CA); cyclin A2 (6E6), cyclin B1 (7A9), and cyclin D1 (DCS-6), from Novocastra (Newcastle upon Tyne, United Kingdom); CDK1 (clone 1), from BD Transduction Laboratories-Pharmingen (San Diego, CA); a-tubulin (DM1A), from Sigma. All antibodies were used at a 1:500 dilution, except HDM2 (1:100), CDK1 (1:1000), and a-tubulin (1:10 000).
